Viveve Medical Inc  

(Public, NASDAQ:VIVE)   Watch this stock  
Find more results for OTC:PLCSF
7.64
-0.31 (-3.90%)
After Hours: 7.64 0.00 (0.00%)
Jun 26, 4:36PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.52 - 7.95
52 week 3.75 - 11.16
Open 7.87
Vol / Avg. 207,362.00/245,106.00
Mkt cap 148.06M
P/E     -
Div/yield     -
EPS -2.24
Shares 19.35M
Beta -0.35
Inst. own 80%
Aug 9, 2017
Q2 2017 Viveve Medical Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 11, 2017
Q1 2017 Viveve Medical Inc Earnings Call
May 11, 2017
Q1 2017 Viveve Medical Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -220.16% -281.63%
Operating margin -210.98% -261.92%
EBITD margin - -260.37%
Return on average assets -98.50% -156.77%
Return on average equity -220.38% -1139.11%
Employees 42 -
CDP Score - -

Address

150 Commercial St
SUNNYVALE, CA 94086-5201
United States - Map
+1-408-5301900 (Phone)
+1-408-5301919 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company's, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician's office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.

Officers and directors

James G. Atkinson Chief Business Officer and President
Age: 57
Bio & Compensation  - Reuters
Patricia K. Scheller Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Scott C. Durbin Chief Financial Officer
Age: 46
Bio & Compensation  - Reuters
Alan Curtis Vice President - Regulatory, Clinical and Quality
Bio & Compensation  - Reuters
Steve Lopez Director - Operations
Bio & Compensation  - Reuters
Lori H. Bush Director
Age: 59
Bio & Compensation  - Reuters
Debora A. Jorn Director
Age: 58
Bio & Compensation  - Reuters
Arlene M. Morris Director
Age: 64
Bio & Compensation  - Reuters
Jon M. Plexico Director
Age: 48
Bio & Compensation  - Reuters
Daniel S. Janney Independent Director
Age: 51
Bio & Compensation  - Reuters